Global Intravenous Immunoglobulins Market 2017-2021
About Intravenous Immunoglobulins
Immunoglobulins are glycoprotein molecules produced by plasma cells. They are a critical part of a body's immune response and they do so by specifically recognizing and binding to microbes and destroying them. These immunoglobulins are produced by a body naturally, but due to some genetic or infectious diseases, the natural production of immunoglobulin is inhibited, resulting in an immune-compromised condition.
Technavio’s analysts forecast the global intravenous immunoglobulins market to grow at a CAGR of 7.62% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global intravenous immunoglobulins market for 2017-2021. To calculate the market size, the report considers sales from both generic and branded drugs.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Intravenous Immunoglobulins Market 2017-2021
Technavio recognizes the following companies as the key players in the global intravenous immunoglobulins market: CSL Behring, Grifols, Octapharma, and Shire.
Other Prominent Vendors in the market are: ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is monetary support to plasma donors. The intravenous immunoglobulin market is growing at steady rate, where the number of plasma donors affects the overall supply chain. Therefore, to maintain and meet the demands of plasma-derived therapeutics, a plasma donor receives monetary compensation.”
According to the report, one driver in the market is growing number of fractionating units. Fractionation is a crucial step in the manufacture of immunoglobulins. This step involves separation of immunoglobulins and other blood protein from plasma. The capacity of fractionating units is increasing. Data estimates suggest that during 2013-2016, the capacity increased by 39.5%. This increased capacity is primarily due to the installment of new fractionating units or expansion of existing fractionating units.
Further, the report states that one challenge in the market is complex and cost-intensive manufacturing. Immunoglobulin manufacturing involves complex, time and cost consuming stages. The process starts from collection of plasma from volunteers. It is followed by plasma fractionation coupled with virus and prion removals. This step is followed by in-vitro testing, which ensures the safety, efficacy and potency of manufactured immunoglobulin.
CSL Behring, Grifols, Octapharma, Shire, ADMA Biologics, Bayer, Bharat Serum and Vaccines, Biotest AG, China Biologic Products, Hualan Biological Engineering, Kedrion Biopharma, LFB Group, and Sanquin.